Prosecution Insights
Last updated: November 04, 2026
Application No. 19/001,442

COMPOSITION FOR PREVENTING AND/OR IMPROVING BRAIN DYSFUNCTION

Non-Final OA §112
Filed
Dec 25, 2024
Examiner
PIHONAK, SARAH
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Institute Of Bioactive Peptides
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
11m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
932 granted / 1518 resolved
+1.4% vs TC avg
Strong +42% interview lift
Without
With
+42.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
37 currently pending
Career history
1561
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
39.3%
-0.7% vs TC avg
§102
10.3%
-29.7% vs TC avg
§112
23.2%
-16.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1518 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application was filed on 12/25/2024. Status of Claims Claims 1-20 are currently pending. Claims 1-20 were examined and are rejected. Claim Rejections-35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for improving a brain dysfunction, does not reasonably provide enablement for preventing a brain dysfunction. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims. See MPEP 2164. The factors to be considered in determining whether a disclosure meets the enablement requirements of 35 U.S.C. 112, first paragraph, have been described in In re Wands, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir., 1988). The court in Wands states, “Enablement is not precluded by the necessity for some experimentation, such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is ‘undue’, not ‘experimentation’” (Wands, 8 USPQ2sd 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. “Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations” (Wands, 8 USPQ2d 1404). Among these factors are: (1) the nature of the invention; (2) the breadth of the claims; (3) the state of the prior art; (4) the predictability or unpredictability of the art; (5) the relative skill of those in the art; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. While all of these factors are considered, a sufficient amount for a prima facie case is discussed below. (1) The nature of the invention and (2) the breadth of the claims: Claims 1-8, 10-14, and 20 recite preventing a brain dysfunction, with diseases characterized by brain dysfunction, such as Alzheimer’s disease, Parkinson’s, ADHD, bipolar disorder, and schizophrenia included. Given that these conditions impact vastly different patient populations and have different etiologies, the scope of the claims is considerably broad. (3) The state of the prior art and (4) the predictability or unpredictability of the art: The state of the art acknowledges prevention of brain dysfunction diseases, such as schizophrenia, Alzheimer’s, and Parkinson’s, has not yet been achieved. The Mayo Clinic teaches while healthy lifestyle habits, such as a healthy diet, exercising regularly, and not smoking, can reduce the risk of developing Alzheimer’s and other types of dementia, effective means of preventing this condition do not currently exist (see pp. 1-2 of “Alzheimer’s prevention: Does it exist?”, Mayo Clinic, publ. 9/25/24). Schizophrenia comprises a spectrum of brain disorders characterized by hallucinations, delusions, disordered thinking and speech, and loss of motivation (see p. 1 of “How to Prevent Schizophrenia Symptoms”, HealthCentral, Peg Rosen, publ. 12/11/2023). Rosen further teaches the causes of schizophrenia are complicated and varied, ranging from having a relative diagnosed with the disease, childhood adversity, and abuse of psychoactive drugs and alcohol during adolescence and young adulthood (p. 2). To date, schizophrenia does not have a cure, and there is no way to prevent the disease (p. 1). Parkinson’s disease develops from a myriad of factors, involving genetics, environmental exposures, aging, and other unknown variables (see “Prevention of Parkinson’s Disease”, Parkinsons.org, publ. March 2026, p. 1). Parkinsons.org teaches that although some measures can lower the risk of developing Parkinson’s disease, such as regular vigorous exercise, caffeine consumption, and a Mediterranean diet, no interventions have yet proven to prevent Parkinson’s (p. 1). Bipolar disorder is characterized by dramatic changes in a person’s mood and energy, ranging from mania to depression; while it cannot be prevented, medications can help control symptoms (“Preventing Bipolar Disorder Episodes”, WebMD, pub. 2/13/26, p. 1, 1st-2nd para). Therefore, while the claims recite preventing brain dysfunction, the art provides ample evidence such disorders cannot be prevented. (5) The relative skill of those in the art: The relative skill of those in the art is considerably high, such as a psychiatrist or neurologist. (6) The amount of direction or guidance presented and (7) the presence or absence of working examples: Applicant has not provided any direction or guidance for preventing brain dysfunction. Although Applicant has shown evidence the combination of DHM, L-theanine, taurine, and cerebroside can improve a brain dysfunction, no such evidence has been provided to indicate the combination can prevent brain dysfunction as claimed. (8) The quantity of experimentation necessary: Considering the state of the art as discussed by the references above, particularly with regards to teachings of the prior art and the high unpredictability in the art as evidenced therein, and the lack of guidance provided in the specification, one of ordinary skill in the art would be burdened with undue experimentation to practice the invention commensurate in the scope of the claims. Dependent claims 9, and 15-19 are similarly rejected as they depend upon a rejected independent claim. To overcome the rejection, it is suggested reference to preventing a brain dysfunction be deleted from the claims. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached Monday-Friday 9:00-5:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. SARAH . PIHONAK Primary Examiner Art Unit 1627 /SARAH PIHONAK/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Dec 25, 2024
Application Filed
Oct 06, 2026
Non-Final Rejection mailed — §112
Oct 27, 2026
Examiner Interview Summary
Oct 27, 2026
Applicant Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778920
METHODS OF TREATING SJÖGRENS SYNDROME
3y 11m to grant Granted Nov 03, 2026
Patent 12773395
O-ACETYLSERINE FOR THE USE THEREOF IN THE PREVENTION AND TREATMENT OF GLUCOSE INTOLERANCE AND THE ASSOCIATED DISEASES
3y 6m to grant Granted Oct 27, 2026
Patent 12773410
EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER
2y 10m to grant Granted Oct 27, 2026
Patent 12760367
TREATMENT OF ATOPIC DERMATITIS WITH TRADIPITANT
3y 11m to grant Granted Oct 13, 2026
Patent 12758557
SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES
3y 3m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
99%
With Interview (+42.3%)
2y 9m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1518 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month